Realizing Chemotherapy as a Therapeutic Option for Prostate Cancer

Dr. Thomas Buckley (2002 Research Grant)

Although, chemotherapy is a popular cancer therapy, it is not as effective for prostate cancer. Chemotherapy is also harmful to healthy cells. As a result, it is not a popular treatment for prostate cancer. In 2002 we granted Dr. Thomas Buckley funds to research a prostate cancer-specific toxin. His work has been very successful; he has developed a drug called PRX302 which selectively and effectively kills PSA-producing cells without harming other tissues.

The results of the initial study were so encouraging that a company, called Protox Therapeutics, was formed to further develop the idea and hopefully bring the discovery to market. The drug is now in phase II clinical trails.

Help us take the first steps toward prevention. Donate Now




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Do men’s toenails contain clues about prostate cancer prevention?

Toronto, January 29, 2018 – Funded by Prostate Cancer Canada (PCC), Dr.
More

Discovery of a promising new medication to block 'master key' of cancer growth

Vancouver, BC – For years, researchers have investigated approaches to prevent cancer-causing cells from multiplying in the body.
More

RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More


Click here for news archive